Form 4: KalVista Pharmaceuticals Acquired in Merger

KalVista Pharmaceuticals, Inc. announced the completion of its merger with Chiesi Farmaceutici S.p.A., with all outstanding shares acquired for $27.00 per share.

Summary

• This filing reports changes in beneficial ownership for Brian Piekos, Chief Financial Officer of KalVista Pharmaceuticals, Inc.
• The transactions are related to the Agreement and Plan of Merger dated April 29, 2026, between KalVista Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., and Skyline Merger Sub, Inc.
• The merger was completed on June 11, 2026, with Skyline Merger Sub, Inc. acquiring all outstanding shares of KalVista Pharmaceuticals, Inc. for $27.00 per share in cash.
• As a result of the merger, all outstanding stock options and restricted stock units (RSUs) held by Brian Piekos became fully vested and were converted into the right to receive cash payments.
• Specifically, 100,000 stock options were converted, and 55,000 and 93,750 RSUs were also converted into cash payments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for the reporting person and shareholders who receive a cash payout, but neutral for the market as it signifies a delisting.

Positives

• The merger provides a cash payout of $27.00 per share to all shareholders, representing a significant return for investors.
• All outstanding stock options and RSUs held by the reporting person were fully vested and converted into cash, realizing the value of these awards.

Negatives

• The acquisition means KalVista Pharmaceuticals, Inc. will no longer be a publicly traded entity, ending its independent status.
• Stock options with an exercise price equal to or greater than the merger consideration were cancelled for no value.

Risks

• The filing mentions that stock options with an exercise price equal to or greater than the merger consideration were cancelled for no consideration, representing a loss for holders of such options.
• The merger agreement itself could be subject to various risks and uncertainties inherent in such transactions, although specific risks are not detailed in this Form 4.

Future Outlook

The future outlook for KalVista Pharmaceuticals, Inc. is now as a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. The company's common stock will cease to be publicly traded.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event in the pharmaceutical industry: the acquisition of a publicly traded company by a larger entity. Such mergers are common as larger pharmaceutical firms seek to acquire innovative pipelines or technologies from smaller biotech companies, often leading to the delisting of the acquired entity.

Stakeholder Impact

• Shareholders: Will receive $27.00 per share in cash, realizing their investment.
• Employees (including management): Outstanding stock options and RSUs have vested and will be converted into cash payments, providing financial benefit.
• Creditors: The acquisition by Chiesi Farmaceutici S.p.A. may impact the terms or continuation of existing debt obligations, though specific impacts are not detailed here.

Next Steps

• KalVista Pharmaceuticals, Inc. will operate as a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.
• Shareholders will receive the merger consideration of $27.00 per share in cash.
• Holders of vested stock options and RSUs will receive cash payments as per the merger agreement.

Key Dates

Keywords

KalVista Pharmaceuticals, Merger, Acquisition, Form 4, SEC Filing, Chiesi Farmaceutici, Stock Options, Restricted Stock Units, Beneficial Ownership, Brian Piekos